{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.53","value":"55.2"},{"groupId":"OG001","spread":"23.66","value":"56.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Global Health Status/QoL: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.03","value":"-2.2"},{"groupId":"OG001","spread":"29.48","value":"-4.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Global Health Status/QoL: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.73","value":"60.0"},{"groupId":"OG001","spread":"27.96","value":"61.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Physical Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.81","value":"1.7"},{"groupId":"OG001","spread":"28.23","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Physical Functioning: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.52","value":"54.9"},{"groupId":"OG001","spread":"36.60","value":"56.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Role Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.25","value":"-0.3"},{"groupId":"OG001","spread":"36.74","value":"-1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Role Functioning: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.09","value":"73.5"},{"groupId":"OG001","spread":"24.84","value":"72.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Emotional Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.70","value":"-2.4"},{"groupId":"OG001","spread":"24.35","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Emotional Functioning: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.97","value":"77.8"},{"groupId":"OG001","spread":"25.92","value":"78.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Cognitive Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.14","value":"-3.2"},{"groupId":"OG001","spread":"24.70","value":"-5.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Cognitive Functioning: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.54","value":"69.1"},{"groupId":"OG001","spread":"33.01","value":"69.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Social Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.56","value":"-2.9"},{"groupId":"OG001","spread":"36.57","value":"-2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Social Functioning: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.30","value":"44.6"},{"groupId":"OG001","spread":"27.69","value":"40.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Fatigue: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.75","value":"-2.3"},{"groupId":"OG001","spread":"31.04","value":"4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Fatigue: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.04","value":"45.6"},{"groupId":"OG001","spread":"33.51","value":"42.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Pain: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.77","value":"-5.5"},{"groupId":"OG001","spread":"34.55","value":"-3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Pain: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.75","value":"7.1"},{"groupId":"OG001","spread":"18.49","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Nausea and Vomiting: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.80","value":"-0.5"},{"groupId":"OG001","spread":"25.22","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Nausea and Vomiting: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.25","value":"26.2"},{"groupId":"OG001","spread":"29.35","value":"24.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Dyspnoea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.86","value":"-3.6"},{"groupId":"OG001","spread":"33.83","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Dyspnoea: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.31","value":"30.3"},{"groupId":"OG001","spread":"32.20","value":"34.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Insomnia: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.06","value":"-1.5"},{"groupId":"OG001","spread":"36.06","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Insomnia: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.14","value":"25.4"},{"groupId":"OG001","spread":"33.04","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"350"}],"units":"Participants"}],"title":"Appetite Loss: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.42","value":"-1.2"},{"groupId":"OG001","spread":"38.65","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Appetite Loss: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.94","value":"25.9"},{"groupId":"OG001","spread":"32.19","value":"24.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Constipation: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.03","value":"-7.1"},{"groupId":"OG001","spread":"35.83","value":"-5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Constipation: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.45","value":"8.2"},{"groupId":"OG001","spread":"16.58","value":"6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Diarrhoea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.72","value":"10.7"},{"groupId":"OG001","spread":"31.73","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Diarrhoea: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.04","value":"12.5"},{"groupId":"OG001","spread":"24.03","value":"12.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"title":"Financial Difficulties: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.42","value":"2.0"},{"groupId":"OG001","spread":"25.61","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Financial Difficulties: End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"351"}],"units":"Participants"}],"description":"EORTC-QLQ-C30 scale was used to assess HRQOL in cancer participants and contains 30 items. Subscale with individual items include physical functioning items 1-5, role functioning items 6-7, emotional functioning items 21-24, cognitive functioning items 20, 25, social functioning items 26-27, quality of life items 29-30, fatigue items 10, 12, 18, nausea and vomiting items 14-15, pain items 9, 19, dyspnoea item 8, insomnia item 11, appetite loss item 13, constipation item 16, diarrhoea item 17, financial difficulties item 28. Raw scores were converted into scale scores ranging from 0 to 100. For the functional scales and the global health status scale, higher scores represent better HRQOL; whereas for the symptom scales lower scores represent better HRQOL. Positive change in functional and global health status scale indicated improvement; negative change for the symptom scales indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG000","title":"Placebo + LenDex"},{"description":"Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).","id":"OG001","title":"Ixazomib + LenDex"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized. Overall number of participants analyzed is the number of participants available for analyses. Number analyzed indicates the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline to approximately 9 years","title":"Change From Baseline in Health-Related Quality of Life (HRQOL) Measured by European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ)-C30 Scale Total Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}